Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Carcinoma, Renal Cell 11Pancreatic Neoplasms 4Multiple Myeloma 4Urinary Bladder Neoplasms 3Leukemia, Myelomonocytic, Chronic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Kidney Neoplasms 3Glioma 3Carcinoma, Non-Small-Cell Lung 3Uveal Melanoma 2Uterine Cervical Neoplasms 2Thyroid Neoplasms 2Thymoma 2Squamous Cell Carcinoma of Head and Neck 2Small Cell Lung Carcinoma 2Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Ovarian Neoplasms 2Oligodendroglioma 2Lymphoma, Large B-Cell, Diffuse 2Lymphoma 2Leukemia, Prolymphocytic 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Mast-Cell 2Leukemia, Large Granular Lymphocytic 2Leukemia, Hairy Cell 2Leukemia, Biphenotypic, Acute 2

Interventions

Cytarabine 18fludarabine phosphate 17Cyclophosphamide 12Busulfan 11Filgrastim 10Peripheral Blood Stem Cell Transplantation 9Etoposide 9Azacitidine 9Methotrexate 8Decitabine 8Antilymphocyte Serum 8Specimen Handling 7Daunorubicin 7Biopsy 7fludarabine 6Tacrolimus 6Stem Cell Transplantation 6Cyclosporine 6decitabine and cedazuridine drug combination 5Melphalan 5Idarubicin 5Topotecan 4Rituximab 4Radiotherapy 4Prednisone 4Mitoxantrone 4Methylprednisolone 4Injections 4venetoclax 3sargramostim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Myelodysplastic Syndromes × Sunitinib × Clear all
NCT00451048 2018-09-04

Sunitinib in Treating Patients With Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia

National Cancer Institute (NCI)

Phase 2 Completed
10 enrolled 9 charts
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myelomonocytic, Chronic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡